Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Alan, regarding the Phase I NCI data with Enhertu, do you expect interim data to be presented at a medical conference like ASCO, or will it be released in a press release? A: Ed, thanks for the question. It has been submitted to either AACR or ASCO. So, I would expect it to be presented at one of those two conferences.
Q: Jeff, can you provide statistics on persistence and compliance for NERLYNX, and what steps are you taking to improve these metrics? A: Yes, Ed. We are educating customers using clinical data showing benefits of staying on therapy for more than 11 months. We work closely with SP partners and sales reps to monitor refills and engage with customers. Our marketing team is also creating materials to support patients throughout their therapy. Data shows about 5% to 10% more patients remain on therapy when starting at a lower dose.
Q: The revenue guidance for the year seems flat. How are you considering price versus volume in that guidance? A: We see a decrease in product supply revenue in 2025 versus 2024. We took a 7% price increase in early Q1 2025. Demand declined about 9% or 10% year over year last year, and we are forecasting a demand decline of about 2% for this year.
Q: Regarding the royalty stream from outside the US, you mentioned China would be down. Should we expect China to be lumpy with revenue boluses and then nothing again in 2025? A: Yes, Ed. China's revenue is lumpy due to its distribution network. We built up inventory ahead of transferring registration authorization to Pierre Fabre, so shipments will be lower in 2025, contributing to the decline in royalties.
Q: On the breast cancer trial for alisertib, what are your expectations for the interim data? A: We will have a better idea of patient numbers in the next earnings call. Patients are randomized to one of three doses, and we expect early response and duration data. The TBCRC 041 trial, with a median PFS of 5.5 months, serves as a benchmark.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。